

# Antonio Pisani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6430598/publications.pdf>

Version: 2024-02-01

388  
papers

22,368  
citations

7069

78  
h-index

13727

129  
g-index

397  
all docs

397  
docs citations

397  
times ranked

19861  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adult-onset sporadic chorea: real-world data from a single-centre retrospective study. <i>Neurological Sciences</i> , 2022, 43, 387-392.	0.9	6
2	Synaptic effects of ethanol on striatal circuitry: therapeutic implications for dystonia. <i>FEBS Journal</i> , 2022, 289, 5834-5849.	2.2	4
3	Lessons learned from people with neurological diseases at the time of COVID-19: The EFNA-EAN survey. <i>European Journal of Neurology</i> , 2022, 29, 318-323.	1.7	7
4	Plasticity, genetics and epigenetics in dystonia: An update. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2022, 184, 199-206.	1.0	3
5	Diagnostic and Prognostic Value of External Anal Sphincter EMG Patterns in Multiple System Atrophy. <i>Movement Disorders</i> , 2022, , .	2.2	4
6	The Impact of Wearable Electronics in Assessing the Effectiveness of Levodopa Treatment in Parkinson's Disease. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2022, 26, 2920-2928.	3.9	9
7	Alpha-Synuclein is Involved in <sc>DYT1</sc> Dystonia Striatal Synaptic Dysfunction. <i>Movement Disorders</i> , 2022, 37, 949-961.	2.2	7
8	Non-Invasive Neuromodulation in the Rehabilitation of Pisa Syndrome in Parkinson's Disease: A Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2022, 13, 849820.	1.1	4
9	COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper. <i>European Journal of Neurology</i> , 2022, 29, 2163-2172.	1.7	13
10	EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic. <i>European Journal of Neurology</i> , 2021, 28, 7-14.	1.7	27
11	The European Academy of Neurology COVID-19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID-19. <i>European Journal of Neurology</i> , 2021, 28, 3303-3323.	1.7	38
12	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic" neurology. <i>European Journal of Neurology</i> , 2021, 28, 1752-1758.	1.7	45
13	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 448-454.	1.8	16
14	Effect of Gabapentin in a Neuropathic Pain Model in Mice Overexpressing Human Wild-Type or Human Mutated Torsin A. <i>Life</i> , 2021, 11, 41.	1.1	2
15	Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective. <i>European Journal of Neurology</i> , 2021, 28, 3226-3229.	1.7	13
16	A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology. <i>European Journal of Neurology</i> , 2021, 28, 3849-3855.	1.7	14
17	Striatal and cerebellar vesicular acetylcholine transporter expression is disrupted in human DYT1 dystonia. <i>Brain</i> , 2021, 144, 909-923.	3.7	22
18	A2A Receptor Dysregulation in Dystonia DYT1 Knock-Out Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2691.	1.8	7

#	ARTICLE	IF	CITATIONS
19	Functional motor phenotypes: to lump or to split?. <i>Journal of Neurology</i> , 2021, 268, 4737-4743.	1.8	25
20	Vesicular Acetylcholine Transporter Alters Cholinergic Tone and Synaptic Plasticity in <scp>DYT1</scp> Dystonia. <i>Movement Disorders</i> , 2021, 36, 2768-2779.	2.2	10
21	Facemasks and face recognition: Potential impact on synaptic plasticity. <i>Neurobiology of Disease</i> , 2021, 153, 105319.	2.1	19
22	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 70-74.	1.1	8
23	Rescue of striatal long-term depression by chronic mGlu5 receptor negative allosteric modulation in distinct dystonia models. <i>Neuropharmacology</i> , 2021, 192, 108608.	2.0	11
24	Effects of head trauma and sport participation in young-onset Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2021, 128, 1185-1193.	1.4	11
25	Generalized Finite-Length Fibonacci Sequences in Healthy and Pathological Human Walking: Comprehensively Assessing Recursivity, Asymmetry, Consistency, Self-Similarity, and Variability of Gaits. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 649533.	1.0	8
26	Neuropathological findings from COVIDâ€™19 patients with neurological symptoms argue against a direct brain invasion of SARSâ€™CoVâ€™2: A critical systematic review. <i>European Journal of Neurology</i> , 2021, 28, 3856-3865.	1.7	64
27	Sudden Onset, Fixed Dystonia and Acute Peripheral Trauma as Diagnostic Clues for Functional Dystonia. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1107-1111.	0.8	5
28	Exploitation of Thermal Sensitivity and Hyperalgesia in a Mouse Model of Dystonia. <i>Life</i> , 2021, 11, 985.	1.1	1
29	Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinsonâ€™s disease cohort. <i>Npj Parkinson's Disease</i> , 2021, 7, 82.	2.5	10
30	Functional gait disorders: Demographic and clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 32-36.	1.1	4
31	Second hit hypothesis in dystonia: Dysfunctional cross talk between neuroplasticity and environment?. <i>Neurobiology of Disease</i> , 2021, 159, 105511.	2.1	14
32	Machine Learning-based Voice Assessment for the Detection of Positive and Recovered COVID-19 Patients. <i>Journal of Voice</i> , 2021, , .	0.6	20
33	Assessment of Motor Impairments in Early Untreated Parkinson's Disease Patients: The Wearable Electronics Impact. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 120-130.	3.9	45
34	Technology-Based Objective Measures Detect Subclinical Axial Signs in Untreated, de novo Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 113-122.	1.5	25
35	Impaired dopamine- and adenosine-mediated signaling and plasticity in a novel rodent model for DYT25 dystonia. <i>Neurobiology of Disease</i> , 2020, 134, 104634.	2.1	22
36	Systemic Activation of Nrf2 Pathway in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 180-184.	2.2	66

#	ARTICLE	IF	CITATIONS
37	Clinical course of paroxysmal dyskinesias throughout pregnancy. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 19-20.	1.1	5
38	A Dual Centre Study of Pain in Parkinson's Disease and Its Relationship with Other Non-Motor Symptoms. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1817-1825.	1.5	17
39	The neuroligins and the synaptic pathway in Autism Spectrum Disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 119, 37-51.	2.9	40
40	Physical Activity Changes and Correlate Effects in Patients with Parkinson's Disease during COVID-19 Lockdown. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 797-802.	0.8	53
41	GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. <i>Movement Disorders</i> , 2020, 35, 2106-2111.	2.2	83
42	Idiopathic Non-task-specific Upper Limb Dystonia, a Neglected Form of Dystonia. <i>Movement Disorders</i> , 2020, 35, 2038-2045.	2.2	21
43	Autonomic symptoms, cardiovascular and sudomotor evaluation in de novo type 1 narcolepsy. <i>Clinical Autonomic Research</i> , 2020, 30, 557-562.	1.4	9
44	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 920-929.	0.8	45
45	Autonomic functions in focal epilepsy: A comparison between lacosamide and carbamazepine monotherapy. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117095.	0.3	5
46	Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. <i>Journal of Neural Transmission</i> , 2020, 127, 1435-1439.	1.4	22
47	Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry. <i>Frontiers in Neurology</i> , 2020, 11, 906.	1.1	6
48	Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. <i>Neurological Sciences</i> , 2020, 41, 1373-1375.	0.9	59
49	The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. <i>European Journal of Neurology</i> , 2020, 27, 1727-1737.	1.7	90
50	Excess Lipin enzyme activity contributes to TOR1A recessive disease and DYT-TOR1A dystonia. <i>Brain</i> , 2020, 143, 1746-1765.	3.7	22
51	Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features. <i>Neurobiology of Aging</i> , 2020, 90, 119-124.	1.5	41
52	Is transcranial direct current stimulation (tDCS) effective for chronic low back pain? A systematic review and meta-analysis. <i>Journal of Neural Transmission</i> , 2020, 127, 1257-1270.	1.4	22
53	Amyloid- $\beta$ 242/Neurogranin Ratio as a Potential Index for Cognitive Impairment in Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1171-1178.	1.2	11
54	Optogenetic Activation of Striatopallidal Neurons Reveals Altered HCN Gating in DYT1 Dystonia. <i>Cell Reports</i> , 2020, 31, 107644.	2.9	16

#	ARTICLE	IF	CITATIONS
55	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 40-43.	1.1	18
56	Does SARS-CoV-2 invade the brain? Translational lessons from animal models. <i>European Journal of Neurology</i> , 2020, 27, 1764-1773.	1.7	214
57	Ischemic injury precipitates neuronal vulnerability in Parkinson's disease: Insights from PINK1 mouse model study and clinical retrospective data. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 57-63.	1.1	16
58	Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 57-59.	1.1	0
59	Models of dystonia: an update. <i>Journal of Neuroscience Methods</i> , 2020, 339, 108728.	1.3	11
60	Long-term treatment with rotigotine in drug-naïve PSP patients. <i>Acta Neurologica Belgica</i> , 2019, 119, 113-116.	0.5	3
61	Dystonia and dopamine: From phenomenology to pathophysiology. <i>Progress in Neurobiology</i> , 2019, 182, 101678.	2.8	53
62	Loss of Non-Apoptotic Role of Caspase-3 in the PINK1 Mouse Model of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3407.	1.8	18
63	The neurobiological basis for novel experimental therapeutics in dystonia. <i>Neurobiology of Disease</i> , 2019, 130, 104526.	2.1	25
64	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease. <i>Nature Communications</i> , 2019, 10, 3945.	5.8	127
65	Editorial for neurobiology of disease special issue on dystonia progress in the neurobiology of dystonia. <i>Neurobiology of Disease</i> , 2019, 130, 104480.	2.1	0
66	Neurotensin receptors inhibit mGluR I responses in nigral dopaminergic neurons via a process that undergoes functional desensitization by G-protein coupled receptor kinases. <i>Neuropharmacology</i> , 2019, 155, 76-88.	2.0	5
67	The effect of postural deformities on back function and pain in patients with Parkinson's disease. <i>NeuroRehabilitation</i> , 2019, 44, 419-424.	0.5	12
68	Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. <i>Epilepsy and Behavior</i> , 2019, 94, 178-182.	0.9	14
69	Rescue of dopamine D2 receptor levels and signaling in DYT1 dystonia mouse models. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	44
70	Dietary Vitamin E as a Protective Factor for Parkinson's Disease: Clinical and Experimental Evidence. <i>Frontiers in Neurology</i> , 2019, 10, 148.	1.1	89
71	Association between physical activity and dementia risk factors in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 319-325.	1.4	26
72	The influence of postural deformities on neck function and pain in patients with Parkinson's disease. <i>NeuroRehabilitation</i> , 2019, 44, 79-84.	0.5	10

#	ARTICLE	IF	CITATIONS
73	Wearable Electronics Assess the Effectiveness of Transcranial Direct Current Stimulation on Balance and Gait in Parkinson's Disease Patients. <i>Sensors</i> , 2019, 19, 5465.	2.1	8
74	CSF $\alpha$ -synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 203-206.	1.1	30
75	Does continuous positive airway pressure treatment affect autonomic nervous system in patients with severe obstructive sleep apnea?. <i>Sleep Medicine</i> , 2018, 42, 68-72.	0.8	9
76	Dopaminergic involvement in a drummer with focal dystonia: A case study. <i>Clinical Neurology and Neurosurgery</i> , 2018, 166, 54-55.	0.6	2
77	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. <i>Journal of Neural Transmission</i> , 2018, 125, 673-679.	1.4	31
78	Motor involvement in Fabry disease. <i>Molecular Genetics and Metabolism Reports</i> , 2018, 14, 43.	0.4	4
79	Does Pisa syndrome affect upper limb function in patients with Parkinson's disease? An observational cross-sectional study. <i>NeuroRehabilitation</i> , 2018, 42, 143-148.	0.5	10
80	Promising rodent models in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S10-S14.	1.1	9
81	Quercetin protects against radiocontrast medium toxicity in human renal proximal tubular cells. <i>Journal of Cellular Physiology</i> , 2018, 233, 4116-4125.	2.0	16
82	The neurobiological bases of autism spectrum disorders: the R451C $\alpha$ -neuroigin 3 mutation hampers the expression of long-term synaptic depression in the dorsal striatum. <i>European Journal of Neuroscience</i> , 2018, 47, 701-708.	1.2	44
83	Enhanced mu opioid receptor-dependent opioidergic modulation of striatal cholinergic transmission in DYT1 dystonia. <i>Movement Disorders</i> , 2018, 33, 310-320.	2.2	20
84	Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 529-538.	0.7	18
85	Pisa Syndrome in Parkinson's Disease: Evidence for Bilateral Vestibulospinal Dysfunction. <i>Parkinson's Disease</i> , 2018, 2018, 1-6.	0.6	6
86	Daytime autonomic activity in idiopathic rapid eye movement sleep behavior disorder: a preliminary study. <i>Sleep Medicine</i> , 2018, 52, 163-167.	0.8	19
87	Dystonia. <i>Nature Reviews Disease Primers</i> , 2018, 4, 25.	18.1	223
88	Dystonia: Are animal models relevant in therapeutics?. <i>Revue Neurologique</i> , 2018, 174, 608-614.	0.6	11
89	Early structural and functional plasticity alterations in a susceptibility period of DYT1 dystonia mouse striatum. <i>ELife</i> , 2018, 7, .	2.8	60
90	Reversal of dopamine-mediated firing inhibition through activation of the dopamine transporter in substantia nigra pars compacta neurons. <i>British Journal of Pharmacology</i> , 2018, 175, 3534-3547.	2.7	13

#	ARTICLE	IF	CITATIONS
91	Centrality of Early Synaptopathy in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 103.	1.1	41
92	Amyloid-Mediated Cholinergic Dysfunction in Motor Impairment Related to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 525-532.	1.2	59
93	Dystonia as a network disorder: a concept in evolution. <i>Current Opinion in Neurology</i> , 2018, 31, 498-503.	1.8	57
94	Comments on: "Complementary and alternative therapies for restless legs syndrome: An evidence-based systematic review". <i>Sleep Medicine Reviews</i> , 2018, 40, 215-216.	3.8	1
95	A novel analytical approach to assess dyskinesia in patients with Parkinson disease. , 2018, , .		6
96	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	1.4	25
97	Effects of adjunctive perampanel on sleep quality, daytime somnolence and cognition in refractory focal epilepsy: further data.. <i>Epilepsy and Behavior</i> , 2017, 67, 137-138.	0.9	13
98	The Italian Dystonia Registry: rationale, design and preliminary findings. <i>Neurological Sciences</i> , 2017, 38, 819-825.	0.9	35
99	Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of <i>DYT1</i> Dystonia. <i>Journal of Neuroscience</i> , 2017, 37, 2112-2124.	1.7	19
100	Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis. <i>Neuroradiology</i> , 2017, 59, 563-570.	1.1	30
101	Alterations of functional connectivity of the motor cortex in Fabry disease. <i>Neurology</i> , 2017, 88, 1822-1829.	1.5	19
102	Assessment of serum uric acid as risk factor for tauopathies. <i>Journal of Neural Transmission</i> , 2017, 124, 1105-1108.	1.4	16
103	Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings. <i>Clinical Neurology and Neurosurgery</i> , 2017, 156, 63-65.	0.6	10
104	Facial diplegia resembling bilateral Ramsay Hunt Syndrome. <i>Journal of the Neurological Sciences</i> , 2017, 376, 109-111.	0.3	5
105	The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice. <i>European Journal of Internal Medicine</i> , 2017, 39, 1-8.	1.0	85
106	Author response: Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study. <i>Neurology</i> , 2017, 89, 1842-1843.	1.5	0
107	Redefining the Pulvinar Sign in Fabry Disease. <i>American Journal of Neuroradiology</i> , 2017, 38, 2264-2269.	1.2	26
108	Abnormal striatal plasticity in a <i>DYT11/SGCE</i> myoclonus dystonia mouse model is reversed by adenosine A2A receptor inhibition. <i>Neurobiology of Disease</i> , 2017, 108, 128-139.	2.1	34

#	ARTICLE	IF	CITATIONS
109	Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients. <i>Journal of the American College of Nutrition</i> , 2017, 36, 586-591.	1.1	21
110	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. <i>Internal and Emergency Medicine</i> , 2017, 12, 1059-1067.	1.0	7
111	Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2266-2273.	3.3	31
112	Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group. <i>Molecular Genetics and Metabolism Reports</i> , 2017, 12, 85-91.	0.4	20
113	Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease. <i>Future Cardiology</i> , 2017, 13, 521-527.	0.5	2
114	Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 73-78.	1.4	19
115	Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature. <i>Genetics in Medicine</i> , 2017, 19, 275-282.	1.1	11
116	Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia. <i>Frontiers in Systems Neuroscience</i> , 2017, 11, 43.	1.2	8
117	Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. <i>BioMed Research International</i> , 2017, 2017, 1-11.	0.9	75
118	Genetic variants associated with Fabry disease progression despite enzyme replacement therapy. <i>Oncotarget</i> , 2017, 8, 107558-107564.	0.8	30
119	Assessment of Hearing Impairment in Parkinson's Disease: Implications for Differential Diagnosis and Disease Progression. , 2017, 07, .		4
120	Selective Inactivation of Striatal FosB/Δ FosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia. <i>Biological Psychiatry</i> , 2016, 79, 354-361.	0.7	68
121	Outlining a Population at Risk of Parkinson's Disease: Evidence from a Case-Control Study. <i>Parkinson's Disease</i> , 2016, 2016, 1-7.	0.6	3
122	Pathophysiology of Dystonia. <i>Handbook of Behavioral Neuroscience</i> , 2016, , 929-950.	0.7	5
123	The potential use of biomarkers in predicting contrast-induced acute kidney injury. <i>International Journal of Nephrology and Renovascular Disease</i> , 2016, Volume 9, 205-221.	0.8	45
124	Early synaptic dysfunction in Parkinson's disease: Insights from animal models. <i>Movement Disorders</i> , 2016, 31, 802-813.	2.2	127
125	Mild cerebello-thalamo-cortical impairment in patients with normal dopaminergic scans (SWEDD). <i>Parkinsonism and Related Disorders</i> , 2016, 28, 23-28.	1.1	20
126	Subtle alterations of excitatory transmission are linked to presynaptic changes in the hippocampus of PINK1-deficient mice. <i>Synapse</i> , 2016, 70, 223-230.	0.6	14



#	ARTICLE	IF	CITATIONS
127	Occurrence of Writing Tremor in Patients With Scans Without Evidence of Dopaminergic Deficit. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 421-424.	0.8	2
128	Hyperkinetic disorders and loss of synaptic downscaling. <i>Nature Neuroscience</i> , 2016, 19, 868-875.	7.1	98
129	Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. <i>Journal of Nephrology</i> , 2016, 29, 71-78.	0.9	22
130	What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. <i>International Journal of Surgery</i> , 2016, 28, S172-S176.	1.1	20
131	Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by 123I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 729-739.	3.3	13
132	Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1022-1030.e4.	2.4	45
133	Molecular and clinical studies in five index cases with novel mutations in the GLA gene. <i>Gene</i> , 2016, 578, 100-104.	1.0	20
134	Dopamine-dependent CB1 receptor dysfunction at corticostriatal synapses in homozygous PINK1 knockout mice. <i>Neuropharmacology</i> , 2016, 101, 460-470.	2.0	12
135	Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice. <i>Neurobiology of Disease</i> , 2016, 91, 21-36.	2.1	36
136	6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 433-442.	0.7	27
137	Genetic variants associated with gastrointestinal symptoms in Fabry disease. <i>Oncotarget</i> , 2016, 7, 85895-85904.	0.8	30
138	Double hit mouse model of Parkinson's disease. <i>Oncotarget</i> , 2016, 7, 80109-80110.	0.8	6
139	Heidenhain variant in two patients with inherited V210I Creutzfeldt-Jakob disease. <i>International Journal of Neuroscience</i> , 2016, 126, 381-3.	0.8	14
140	Optogenetic stimulation reveals distinct modulatory properties of thalamostriatal vs corticostriatal glutamatergic inputs to fast-spiking interneurons. <i>Scientific Reports</i> , 2015, 5, 16742.	1.6	42
141	Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. <i>BMC Research Notes</i> , 2015, 8, 711.	0.6	9
142	A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus. <i>Frontiers in Neurology</i> , 2015, 6, 86.	1.1	39
143	Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	20
144	Pituitary function and morphology in Fabry disease. <i>Endocrine</i> , 2015, 50, 483-488.	1.1	5

#	ARTICLE	IF	CITATIONS
145	Reversal of radiocontrast medium toxicity in human renal proximal tubular cells by white grape juice extract. <i>Chemico-Biological Interactions</i> , 2015, 229, 17-25.	1.7	21
146	Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 661-666.	0.4	19
147	Early markers of Fabry disease revealed by proteomics. <i>Molecular BioSystems</i> , 2015, 11, 1543-1551.	2.9	51
148	Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?. <i>Genetics in Medicine</i> , 2015, 17, 21-23.	1.1	5
149	Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia. <i>Progress in Neurobiology</i> , 2015, 127-128, 91-107.	2.8	136
150	Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial. <i>PLoS ONE</i> , 2015, 10, e0118174.	1.1	30
151	Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. <i>Journal of Neurology</i> , 2015, 262, 2164-2170.	1.8	35
152	Cerebellar synaptogenesis is compromised in mouse models of DYT1 dystonia. <i>Experimental Neurology</i> , 2015, 271, 457-467.	2.0	39
153	An investigation of hearing impairment in de-novo Parkinson's disease patients: A preliminary study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 987-991.	1.1	36
154	Atrial septum aneurysm: an unusual manifestation in ADPKD?. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 1206-1207.	0.7	0
155	Rhes regulates dopamine D2 receptor transmission in striatal cholinergic interneurons. <i>Neurobiology of Disease</i> , 2015, 78, 146-161.	2.1	25
156	First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1025-1031.	3.3	71
157	Pisa syndrome in Parkinson disease. <i>Neurology</i> , 2015, 85, 1769-1779.	1.5	72
158	Persistent chorea in DYT6, due to anticholinergic therapy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1282-1283.	1.1	8
159	Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 645-652.	0.4	113
160	Nutritional treatment in chronic kidney disease: the concept of nephroprotection. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 161-167.	0.7	18
161	Prevention of Contrast-Induced Nephropathy through a Knowledge of Its Pathogenesis and Risk Factors. <i>Scientific World Journal</i> , The, 2014, 2014, 1-16.	0.8	86
162	Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M <sub>1</sub> muscarinic receptors. <i>Movement Disorders</i> , 2014, 29, 1655-1665.	2.2	152

#	ARTICLE	IF	CITATIONS
163	Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. <i>Patient Preference and Adherence</i> , 2014, 8, 73.	0.8	33
164	Acute Kidney Injury by Radiographic Contrast Media: Pathogenesis and Prevention. <i>BioMed Research International</i> , 2014, 2014, 1-21.	0.9	95
165	Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia. <i>Neuropharmacology</i> , 2014, 85, 440-450.	2.0	33
166	Delphi consensus on the current clinical and therapeutic knowledge on Andersonâ€™Fabry disease. <i>European Journal of Internal Medicine</i> , 2014, 25, 751-756.	1.0	16
167	Endothelial-mediated coronary flow reserve in patients with Andersonâ€™Fabry disease. <i>International Journal of Cardiology</i> , 2014, 177, 1059-1060.	0.8	1
168	Catheter-Based Renal Denervation in ADPKD: Just for Pain Control?. <i>American Journal of Kidney Diseases</i> , 2014, 64, 999.	2.1	3
169	Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	32
170	Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia. <i>Neurobiology of Disease</i> , 2014, 65, 124-132.	2.1	69
171	Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease. <i>Journal of Inherited Metabolic Disease</i> , 2014, 37, 145-146.	1.7	5
172	Renal Sympatheticâ€™Nerve Ablation for Uncontrolled Hypertension in a Patient With Singleâ€™Kidney Autosomal Dominant Polycystic Kidney Disease. <i>Journal of Clinical Hypertension</i> , 2014, 16, 385-386.	1.0	11
173	Fanconi syndrome with lysinuric protein intolerance. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 599-601.	1.4	13
174	A strange epigastric pain. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 493-494.	1.4	1
175	<i>PINK1</i> heterozygous mutations induce subtle alterations in dopamineâ€™dependent synaptic plasticity. <i>Movement Disorders</i> , 2014, 29, 41-53.	2.2	40
176	CSF biomarkers in superficial siderosis: a new tool for diagnosis and evaluation of therapeutic efficacy of deferiproneâ€™a case report. <i>Neurological Sciences</i> , 2014, 35, 1151-1152.	0.9	7
177	Arterial aneurysms: autosomal dominant polycystic kidney disease, Marfan syndrome or both?. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 672-673.	0.7	1
178	Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 850-863.	3.0	199
179	The kidney in Fabry's disease. <i>Clinical Genetics</i> , 2014, 86, 301-309.	1.0	48
180	Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, F1243-F1250.	1.3	16

#	ARTICLE	IF	CITATIONS
181	Differential Activation of Signaling Pathways by Low-Osmolar and Iso-Osmolar Radiocontrast Agents in Human Renal Tubular Cells. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 281-289.	1.2	33
182	Effects of Two Weeks of Cerebellar Theta Burst Stimulation in Cervical Dystonia Patients. <i>Brain Stimulation</i> , 2014, 7, 564-572.	0.7	124
183	Complications of Native Arteriovenous Fistula: The Role of Color Doppler Ultrasonography. <i>Therapeutic Apheresis and Dialysis</i> , 2014, 18, 155-161.	0.4	12
184	Powerful inhibitory action of mu opioid receptors (MOR) on cholinergic interneuron excitability in the dorsal striatum. <i>Neuropharmacology</i> , 2013, 75, 78-85.	2.0	43
185	Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury. <i>Clinical and Experimental Nephrology</i> , 2013, 18, 424-31.	0.7	46
186	Pleural effusion in peritoneal dialysis: overload or leakage?. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 907-907.	0.7	3
187	Polycystic horseshoe kidney. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 905-906.	0.7	1
188	New genetic insights highlight "old" ideas on motor dysfunction in dystonia. <i>Trends in Neurosciences</i> , 2013, 36, 717-725.	4.2	51
189	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. <i>Lancet</i> , The, 2013, 382, 1485-1495.	6.3	218
190	Early abnormalities in 123I-ioflupane (DaTSCAN) imaging in the fragile X-associated tremor ataxia syndrome (FXTAS): a case report. <i>Neurological Sciences</i> , 2013, 34, 1475-1477.	0.9	6
191	Role of Reactive Oxygen Species in Pathogenesis of Radiocontrast-Induced Nephropathy. <i>BioMed Research International</i> , 2013, 2013, 1-6.	0.9	82
192	Engineering animal models of dystonia. <i>Movement Disorders</i> , 2013, 28, 990-1000.	2.2	51
193	Torsin A Localization in the Mouse Cerebellar Synaptic Circuitry. <i>PLoS ONE</i> , 2013, 8, e68063.	1.1	24
194	Strength and Weaknesses of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Possible Detection of Overlaps with Frailty Process. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 538-546.	0.8	5
195	Cholinergic Dysfunction Alters Synaptic Integration between Thalamostriatal and Corticostriatal Inputs in DYT1 Dystonia. <i>Journal of Neuroscience</i> , 2012, 32, 11991-12004.	1.7	93
196	Nephrotic syndrome and autosomal dominant polycystic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 508-511.	1.4	9
197	Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3560-3567.	0.4	49
198	Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18985-18990.	3.3	113

#	ARTICLE	IF	CITATIONS
199	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , 2012, 259, 2621-2631.	1.8	188
200	Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature. <i>Molecular Genetics and Metabolism</i> , 2012, 107, 267-275.	0.5	87
201	Aberrant striatal synaptic plasticity in monogenic parkinsonisms. <i>Neuroscience</i> , 2012, 211, 126-135.	1.1	18
202	Neuroscience disease models. <i>Neuroscience</i> , 2012, 211, 1.	1.1	0
203	A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 39.	0.7	16
204	Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2012, 9, 188.	3.1	115
205	How relevant is the cholinergic system in DYT1 dystonia?. <i>Basal Ganglia</i> , 2012, 2, 227-230.	0.3	0
206	Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study. <i>PLoS ONE</i> , 2012, 7, e32533.	1.1	46
207	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012, 33, 585-593.	0.9	18
208	Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. <i>Journal of Inherited Metabolic Disease</i> , 2012, 35, 513-520.	1.7	40
209	Generation of a novel rodent model for DYT1 dystonia. <i>Neurobiology of Disease</i> , 2012, 47, 61-74.	2.1	70
210	Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA. <i>Neurobiology of Disease</i> , 2012, 47, 416-427.	2.1	71
211	Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. <i>Radiologia Medica</i> , 2012, 117, 19-28.	4.7	38
212	A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency. <i>Journal of Nephrology</i> , 2012, 25, 582-585.	0.9	2
213	Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission. <i>Neuropharmacology</i> , 2011, 61, 632-637.	2.0	36
214	Altered profile and D2-dopamine receptor modulation of high voltage-activated calcium current in striatal medium spiny neurons from animal models of Parkinson's disease. <i>Neuroscience</i> , 2011, 177, 240-251.	1.1	15
215	Abnormal plasticity in dystonia: Disruption of synaptic homeostasis. <i>Neurobiology of Disease</i> , 2011, 42, 162-170.	2.1	144
216	Towards a new era for dystonia, a high priority for biomedical research. <i>Neurobiology of Disease</i> , 2011, 42, 125-126.	2.1	5

#	ARTICLE	IF	CITATIONS
217	Centrality of Striatal Cholinergic Transmission in Basal Ganglia Function. <i>Frontiers in Neuroanatomy</i> , 2011, 5, 6.	0.9	113
218	Putaminal, but not nigral alterations, characterize hemiparkinsonism-hemiatrophy syndrome: A case report. <i>Movement Disorders</i> , 2011, 26, 352-354.	2.2	5
219	Homeostatic changes of the endocannabinoid system in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 216-222.	2.2	45
220	Experimental Models of Dystonia. <i>International Review of Neurobiology</i> , 2011, 98, 551-572.	0.9	15
221	Clinical treatment of polycystic kidney disease (APKD): do we need further suggestions from rodents?. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2065-2066.	0.4	3
222	Developmental Profile of the Aberrant Dopamine D2 Receptor Response in Striatal Cholinergic Interneurons in DYT1 Dystonia. <i>PLoS ONE</i> , 2011, 6, e24261.	1.1	77
223	Simultaneous multicystic kidney and Anderson-Fabry disease: 2 separate entities or same side of the coin. <i>Journal of Nephrology</i> , 2011, 24, 806-808.	0.9	9
224	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010, 257, 5-14.	1.8	140
225	Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. <i>Neurobiology of Disease</i> , 2010, 38, 434-445.	2.1	92
226	Mycophenolic acid inhibits the phosphorylation of NF- $\kappa$ B and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. <i>Chemico-Biological Interactions</i> , 2010, 185, 253-262.	1.7	35
227	Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. <i>Movement Disorders</i> , 2010, 25, 920-924.	2.2	65
228	Role of Aberrant Striatal Dopamine D <sub>1</sub> Receptor/cAMP/Protein Kinase A/DARPP32 Signaling in the Paradoxical Calming Effect of Amphetamine. <i>Journal of Neuroscience</i> , 2010, 30, 11043-11056.	1.7	66
229	Effects of mycophenolate mofetil on acute ischaemia-reperfusion injury in rats and its consequences in the long term. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1443-1450.	0.4	10
230	Cardiac magnetic resonance imaging illustrating Anderson's Fabry disease progression. <i>British Journal of Radiology</i> , 2010, 83, e249-e251.	1.0	11
231	Electrophysiology of 5-HT <sub>6</sub> Receptors. <i>International Review of Neurobiology</i> , 2010, 94, 111-128.	0.9	10
232	Dopaminergic Agonists and L-DOPA. , 2009, , 601-607.		0
233	R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 14622-14627.	3.3	264
234	Levodopa-induced dyskinesia and striatal signaling pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2973-2974.	3.3	6

#	ARTICLE	IF	CITATIONS
235	Setting dialysis start at 6.0 ml/min/1.73 m <sup>2</sup> eGFR—a study on safety, quality of life and economic impact. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3434-3440.	0.4	26
236	Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. <i>Heart</i> , 2009, 95, 1103-1107.	1.2	71
237	Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. <i>Brain</i> , 2009, 132, 2336-2349.	3.7	197
238	Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. <i>Neurobiology of Disease</i> , 2009, 34, 133-145.	2.1	80
239	Effect of a Low- Versus Moderate-Protein Diet on Progression of CKD: Follow-up of a Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2009, 54, 1052-1061.	2.1	64
240	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1641-1649.	2.2	1,171
241	Seletracetam (ucb 44212) inhibits high-voltage-activated Ca <sup>2+</sup> currents and intracellular Ca <sup>2+</sup> increase in rat cortical neurons in vitro. <i>Epilepsia</i> , 2009, 50, 702-710.	2.6	14
242	Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment. <i>Journal of Neurochemistry</i> , 2009, 109, 1096-1105.	2.1	65
243	Impaired dopamine release and synaptic plasticity in the striatum of <i>Parkin</i> <sup>-/-</sup> mice. <i>Journal of Neurochemistry</i> , 2009, 110, 613-621.	2.1	119
244	ECMPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 617-624.	1.0	30
245	Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin. <i>Experimental Neurology</i> , 2009, 215, 388-396.	2.0	37
246	Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 383-389.	1.1	46
247	Cholinergic Interneuron and Parkinsonism. , 2009, , 1-11.		0
248	Pedunculopontine nucleus deep brain stimulation changes spinal cord excitability in Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2008, 115, 731-735.	1.4	59
249	Antiepileptic Drugs on Calcium Currents Recorded from Cortical and PAG Neurons: Therapeutic Implications for Migraine. <i>Cephalalgia</i> , 2008, 28, 1315-1326.	1.8	37
250	Cardiac performance during exercise in patients with Fabry's disease. <i>European Journal of Clinical Investigation</i> , 2008, 38, 910-917.	1.7	10
251	Distinct roles of group I mGlu receptors in striatal function. <i>Neuropharmacology</i> , 2008, 55, 392-395.	2.0	32
252	Age-related functional changes of high-voltage-activated calcium channels in different neuronal subtypes of mouse striatum. <i>Neuroscience</i> , 2008, 152, 469-476.	1.1	17

#	ARTICLE	IF	CITATIONS
253	Sleep quality in patients with chronic renal failure: A 3-year longitudinal study. <i>Sleep Medicine</i> , 2008, 9, 240-246.	0.8	47
254	Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 1628-1635.	0.4	44
255	Loss of Muscarinic Autoreceptor Function Impairs Long-Term Depression But Not Long-Term Potentiation in the Striatum. <i>Journal of Neuroscience</i> , 2008, 28, 6258-6263.	1.7	81
256	Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. <i>Neurology</i> , 2007, 68, 1455-1459.	1.5	78
257	Endogenous Serotonin Excites Striatal Cholinergic Interneurons via the Activation of 5-HT <sub>2C</sub> , 5-HT <sub>6</sub> , and 5-HT <sub>7</sub> Serotonin Receptors: Implications for Extrapyramidal Side Effects of Serotonin Reuptake Inhibitors. <i>Neuropsychopharmacology</i> , 2007, 32, 1840-1854.	2.8	122
258	MRI Characterization of Myocardial Tissue in Patients with Fabry's Disease. <i>American Journal of Roentgenology</i> , 2007, 188, 850-853.	1.0	36
259	Metabolic effects of two low protein diets in chronic kidney disease stage 4-5—a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 636-644.	0.4	93
260	Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 11441-11446.	3.3	472
261	Re-emergence of striatal cholinergic interneurons in movement disorders. <i>Trends in Neurosciences</i> , 2007, 30, 545-553.	4.2	400
262	Functional and ultrastructural analysis of group I mGluR in striatal fast-spiking interneurons. <i>European Journal of Neuroscience</i> , 2007, 25, 1319-1331.	1.2	13
263	Neuroacanthocytosis associated with a defect of the 4.1R membrane protein. <i>BMC Neurology</i> , 2007, 7, 4.	0.8	6
264	Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. <i>Amino Acids</i> , 2007, 32, 189-195.	1.2	39
265	Central Acute D <sub>2</sub> Stimulation Worsens Bladder Function in Patients With Mild Parkinson's Disease. <i>Journal of Urology</i> , 2006, 175, 202-206.	0.2	49
266	Chronic Cocaine Prevents Depotentiation at Corticostriatal Synapses. <i>Biological Psychiatry</i> , 2006, 60, 436-443.	0.7	43
267	Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: The role of endogenous acetylcholine. <i>Neuropharmacology</i> , 2006, 50, 917-923.	2.0	27
268	NR2B Subunit Exerts a Critical Role in Postischemic Synaptic Plasticity. <i>Stroke</i> , 2006, 37, 1895-1901.	1.0	63
269	Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease. <i>European Journal of Neuroscience</i> , 2006, 23, 2923-2928.	1.2	114
270	Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons. <i>Neurobiology of Disease</i> , 2006, 22, 143-152.	2.1	79



#	ARTICLE	IF	CITATIONS
271	Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: Role of Na <sup>+</sup> /K <sup>+</sup> ATPase. <i>Neurobiology of Disease</i> , 2006, 23, 54-60.	2.1	51
272	Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia. <i>Neurobiology of Disease</i> , 2006, 24, 318-325.	2.1	150
273	Multiple Mechanisms Underlying the Neuroprotective Effects of Antiepileptic Drugs Against In Vitro Ischemia. <i>Stroke</i> , 2006, 37, 1319-1326.	1.0	95
274	Endocrine Dysfunction in Patients with Fabry Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4319-4325.	1.8	46
275	Mitochondrial Toxins in Basal Ganglia Disorders: From Animal Models to Therapeutic Strategies. <i>Current Neuropharmacology</i> , 2006, 4, 69-75.	1.4	23
276	Inhibition of Ras/ERK1/2 signaling protects against posts ischemic renal injury. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, F1408-F1415.	1.3	46
277	Inhibition of Persistent Sodium Current Fraction and Voltage-gated L-type Calcium Current by Propofol in Cortical Neurons: Implications for Its Antiepileptic Activity. <i>Epilepsia</i> , 2005, 46, 624-635.	2.6	46
278	Enzyme Replacement Therapy in Fabry Disease Patients Undergoing Dialysis: Effects on Quality of Life and Organ Involvement. <i>American Journal of Kidney Diseases</i> , 2005, 46, 120-127.	2.1	63
279	High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. <i>Annals of Neurology</i> , 2005, 57, 777-779.	2.8	150
280	Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 395-402.	2.2	141
281	Prevalence of Hepatitis C Virus Infection in Different Population Groups in Southern Italy. <i>Infection</i> , 2005, 33, 9-12.	2.3	20
282	Acanthocytosis as a predisposing factor for non-ketotic hyperglycaemia induced chorea-ballism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1717-1719.	0.9	33
283	Sleep quality in renal transplant patients: a never investigated problem. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 194-198.	0.4	80
284	Pathological Synaptic Plasticity in the Striatum: Implications for Parkinson's Disease. <i>NeuroToxicology</i> , 2005, 26, 779-783.	1.4	80
285	Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1. <i>Neuron</i> , 2005, 45, 489-496.	3.8	485
286	Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons. <i>Neuropharmacology</i> , 2005, 49, 104-113.	2.0	64
287	Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. <i>Neuroscience</i> , 2005, 133, 831-840.	1.1	54
288	Short and Long Term Modulation of Synaptic Activity in Striatal Cholinergic Interneurons. , 2005, , 91-97.		0

#	ARTICLE	IF	CITATIONS
289	Coordinate high-frequency pattern of stimulation and calcium levels control the induction of LTP in striatal cholinergic interneurons. <i>Learning and Memory</i> , 2004, 11, 755-760.	0.5	23
290	Atorvastatin Improves the Course of Ischemic Acute Renal Failure in Aging Rats. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 901-909.	3.0	68
291	Enzyme replacement therapy with agalsidase $\hat{2}$ improves cardiac involvement in Fabry's disease. <i>Clinical Genetics</i> , 2004, 66, 158-165.	1.0	109
292	Intracellular Calcium Increase in Epileptiform Activity: Modulation by Levetiracetam and Lamotrigine. <i>Epilepsia</i> , 2004, 45, 719-728.	2.6	124
293	Calcium signaling and neuronal vulnerability to ischemia in the striatum. <i>Cell Calcium</i> , 2004, 36, 277-284.	1.1	32
294	Early ionic and membrane potential changes caused by the pesticide rotenone in striatal cholinergic interneurons. <i>Experimental Neurology</i> , 2004, 185, 169-181.	2.0	20
295	Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. <i>Progress in Neurobiology</i> , 2004, 74, 271-300.	2.8	139
296	Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum. <i>Neuroscience</i> , 2004, 129, 157-166.	1.1	77
297	Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 9-20.	1.0	47
298	Glutamate Transmission in the Pathogenesis of Parkinson's Disease. , 2004, , 229-242.		1
299	The Concept of 'Neuroprotection' in Neurological Diseases. <i>Current Neuropharmacology</i> , 2004, 2, 261-263.	1.4	0
300	Synaptic plasticity in the ischaemic brain. <i>Lancet Neurology</i> , The, 2003, 2, 622-629.	4.9	139
301	Behavioural learning-induced increase in spontaneous GABAA-dependent synaptic activity in rat striatal cholinergic interneurons. <i>European Journal of Neuroscience</i> , 2003, 17, 174-178.	1.2	11
302	Targeting striatal cholinergic interneurons in Parkinson's disease: Focus on metabotropic glutamate receptors. <i>Neuropharmacology</i> , 2003, 45, 45-56.	2.0	85
303	Zaleplon Improves Sleep Quality in Maintenance Hemodialysis Patients. <i>Nephron Clinical Practice</i> , 2003, 94, c99-c103.	2.3	30
304	Dopamine, Acetylcholine and Nitric Oxide Systems Interact to Induce Corticostriatal Synaptic Plasticity. <i>Reviews in the Neurosciences</i> , 2003, 14, 207-16.	1.4	110
305	Stimulus frequency, calcium levels and striatal synaptic plasticity. <i>NeuroReport</i> , 2003, 14, 419-422.	0.6	21
306	The impact of haemoglobin on the quality of sleep in haemodialysis patients: which is the truth?. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1947-1948.	0.4	7

#	ARTICLE	IF	CITATIONS
307	Distinct Roles of D <sub>1</sub> and D <sub>5</sub> Dopamine Receptors in Motor Activity and Striatal Synaptic Plasticity. <i>Journal of Neuroscience</i> , 2003, 23, 8506-8512.	1.7	213
308	Receptor Subtypes Involved in the Presynaptic and Postsynaptic Actions of Dopamine on Striatal Interneurons. <i>Journal of Neuroscience</i> , 2003, 23, 6245-6254.	1.7	209
309	Activation of Î²1-Adrenoceptors Excites Striatal Cholinergic Interneurons through a cAMP-Dependent, Protein Kinase-Independent Pathway. <i>Journal of Neuroscience</i> , 2003, 23, 5272-5282.	1.7	45
310	Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. <i>Brain</i> , 2002, 125, 2635-2645.	3.7	76
311	Tissue plasminogen activator is required for striatal post-ischemic synaptic potentiation. <i>NeuroReport</i> , 2002, 13, 115-118.	0.6	12
312	Post-ischaemic long-term synaptic potentiation in the striatum: a putative mechanism for cell type-specific vulnerability. <i>Brain</i> , 2002, 125, 844-860.	3.7	64
313	Impairment of mitochondrial metabolism differentially affects striatal neuronal subtypes. <i>NeuroReport</i> , 2002, 13, 641-644.	0.6	7
314	Metabotropic Glutamate 2 Receptors Modulate Synaptic Inputs and Calcium Signals in Striatal Cholinergic Interneurons. <i>Journal of Neuroscience</i> , 2002, 22, 6176-6185.	1.7	67
315	Cocaine and Amphetamine Depress Striatal GABAergic Synaptic Transmission through D2 Dopamine Receptors. <i>Neuropsychopharmacology</i> , 2002, 26, 164-175.	2.8	78
316	Dopamine D2 Receptor-Mediated Inhibition of Dopaminergic Neurons in Mice Lacking D2L Receptors. <i>Neuropsychopharmacology</i> , 2002, 27, 723-726.	2.8	79
317	Activation of dopamine D1-like receptors excites LTS interneurons of the striatum. <i>European Journal of Neuroscience</i> , 2002, 15, 2049-2052.	1.2	69
318	Tissue plasminogen activator is required for corticostriatal long-term potentiation. <i>European Journal of Neuroscience</i> , 2002, 16, 713-721.	1.2	52
319	Dopamine-Dependent Long-Term Potentiation Induced by 3-Nitropropionic Acid in Striatal Medium Spiny Neurons. <i>Advances in Behavioral Biology</i> , 2002, , 187-190.	0.2	0
320	Periphery Is Central To Nociception. <i>NeuroReport</i> , 2002, 13, 1376.	0.6	0
321	Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission. <i>Molecular and Cellular Neurosciences</i> , 2001, 17, 1071-1083.	1.0	92
322	Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. <i>Neuroscience</i> , 2001, 106, 579-587.	1.1	292
323	Role of tonically-active neurons in the control of striatal function: Cellular mechanisms and behavioral correlates. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001, 25, 211-230.	2.5	54
324	Ionic mechanisms underlying differential vulnerability to ischemia in striatal neurons. <i>Progress in Neurobiology</i> , 2001, 63, 687-696.	2.8	59

#	ARTICLE	IF	CITATIONS
325	Presynaptic modulation by group III metabotropic glutamate receptors (mGluRs) of the excitatory postsynaptic potential mediated by mGluR1 in rat cerebellar Purkinje cells. <i>Neuroscience Letters</i> , 2001, 310, 61-65.	1.0	11
326	Functional coexpression of excitatory mGluR1 and mGluR5 on striatal cholinergic interneurons. <i>Neuropharmacology</i> , 2001, 40, 460-463.	2.0	55
327	Selective involvement of mGlu1 receptors in corticostriatal LTD. <i>Neuropharmacology</i> , 2001, 40, 839-846.	2.0	104
328	Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine. <i>Journal of Neuroscience</i> , 2001, 21, 5110-5120.	1.7	152
329	Stimulation of Nitric Oxide-cGMP Pathway Excites Striatal Cholinergic Interneurons via Protein Kinase G Activation. <i>Journal of Neuroscience</i> , 2001, 21, 1393-1400.	1.7	44
330	Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. <i>American Journal of Kidney Diseases</i> , 2001, 38, 18-25.	2.1	242
331	Adenosine-mediated inhibition of striatal GABAergic synaptic transmission during in vitro ischaemia. <i>Brain</i> , 2001, 124, 1855-1865.	3.7	38
332	CALCIUM: THE DIRECTOR OF OUR MEMORY PROCESSES. <i>NeuroReport</i> , 2001, 12, A67.	0.6	0
333	Involvement of Intracellular Calcium Stores during Oxygen/Glucose Deprivation in Striatal Large Spiny Interneurons. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 839-846.	2.4	28
334	Cell-type specificity of mGluR activation in striatal neuronal subtypes. <i>Amino Acids</i> , 2000, 19, 119-129.	1.2	28
335	Activation of D2-Like Dopamine Receptors Reduces Synaptic Inputs to Striatal Cholinergic Interneurons. <i>Journal of Neuroscience</i> , 2000, 20, RC69-RC69.	1.7	144
336	Acetylcholine-mediated modulation of striatal function. <i>Trends in Neurosciences</i> , 2000, 23, 120-126.	4.2	400
337	Synaptic transmission in the striatum: from plasticity to neurodegeneration. <i>Progress in Neurobiology</i> , 2000, 61, 231-265.	2.8	254
338	A Critical Role of the Nitric Oxide/cGMP Pathway in Corticostriatal Long-Term Depression. <i>Journal of Neuroscience</i> , 1999, 19, 2489-2499.	1.7	218
339	Electrophysiological Recordings and Calcium Measurements in Striatal Large Spiny Interneurons in Response to Combined Oxygen/Glucose Deprivation. <i>Journal of Neurophysiology</i> , 1999, 81, 2508-2516.	0.9	46
340	An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. <i>British Journal of Pharmacology</i> , 1999, 126, 689-696.	2.7	65
341	Weak effect of neuromodulators on climbing fiber-activated $[Ca^{2+}]_i$ increases in rat cerebellar Purkinje neurons. <i>Brain Research</i> , 1999, 831, 113-118.	1.1	6
342	Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. <i>American Journal of Kidney Diseases</i> , 1999, 33, 851-856.	2.1	228

#	ARTICLE	IF	CITATIONS
343	Metabotropic Glutamate Receptors and Cell-Type-Specific Vulnerability in the Striatum: Implication for Ischemia and Huntington's Disease. <i>Experimental Neurology</i> , 1999, 158, 97-108.	2.0	99
344	Sodium Influx Plays a Major Role in the Membrane Depolarization Induced by Oxygen and Glucose Deprivation in Rat Striatal Spiny Neurons. <i>Stroke</i> , 1999, 30, 171-179.	1.0	70
345	Pharmacological Inhibition of the Na <sup>+</sup> /Ca <sup>2+</sup> Exchanger Enhances Depolarizations Induced by Oxygen/Glucose Deprivation but Not Responses to Excitatory Amino Acids in Rat Striatal Neurons. <i>Stroke</i> , 1999, 30, 1687-1694.	1.0	23
346	Muscarinic IPSPs in rat striatal cholinergic interneurons. <i>Journal of Physiology</i> , 1998, 510, 421-427.	1.3	83
347	Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. <i>European Journal of Neuroscience</i> , 1998, 10, 2887-2895.	1.2	133
348	Hypoglycemia, Hypoxia, and Ischemia in a Corticostriatal Slice Preparation: Electrophysiologic Changes and Ascorbyl Radical Formation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 868-875.	2.4	19
349	Blockade of M2-like muscarinic receptors enhances long-term potentiation at corticostriatal synapses. <i>European Journal of Neuroscience</i> , 1998, 10, 3020-3023.	1.2	89
350	Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: Implications for ischemia and Huntington's disease. <i>Annals of Neurology</i> , 1998, 43, 586-597.	2.8	126
351	Morphological and functional study of dwarf neurons in the rat striatum. <i>European Journal of Neuroscience</i> , 1998, 10, 3575-3583.	1.2	7
352	SHORT COMMUNICATION Early sodium elevations induced by combined oxygen and glucose deprivation in pyramidal cortical neurons. <i>European Journal of Neuroscience</i> , 1998, 10, 3572-3574.	1.2	25
353	Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. <i>Neuropharmacology</i> , 1998, 37, 1063-1070.	2.0	39
354	L-Type Ca <sup>2+</sup> Channel Blockers Attenuate Electrical Changes and Ca <sup>2+</sup> Rise Induced by Oxygen/Glucose Deprivation in Cortical Neurons. <i>Stroke</i> , 1998, 29, 196-202.	1.0	67
355	Hypoxic and hypoglycaemic changes of intracellular pH in cerebral cortical pyramidal neurones. <i>NeuroReport</i> , 1998, 9, 1447-1450.	0.6	8
356	Hypoxia in striatal and cortical neurones. <i>NeuroReport</i> , 1997, 8, 1143-1147.	0.6	15
357	Activation of Group III Metabotropic Glutamate Receptors Depresses Glutamatergic Transmission at Corticostriatal Synapse. <i>Neuropharmacology</i> , 1997, 36, 845-851.	2.0	99
358	Opposite Membrane Potential Changes Induced by Glucose Deprivation in Striatal Spiny Neurons and in Large Spiny Interneurons. <i>Journal of Neuroscience</i> , 1997, 17, 1940-1949.	1.7	65
359	Endogenous Adenosine Mediates the Presynaptic Inhibition Induced by Aglycemia at Corticostriatal Synapses. <i>Journal of Neuroscience</i> , 1997, 17, 4509-4516.	1.7	67
360	Abnormal Synaptic Plasticity in the Striatum of Mice Lacking Dopamine D2 Receptors. <i>Journal of Neuroscience</i> , 1997, 17, 4536-4544.	1.7	279

#	ARTICLE	IF	CITATIONS
361	A Possible Mechanism for the Aglycemia-Induced Depression of Glutamatergic Excitation in the Striatum. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 1121-1126.	2.4	14
362	Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. <i>British Journal of Pharmacology</i> , 1997, 120, 1007-1014.	2.7	193
363	Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. <i>Neuroscience and Biobehavioral Reviews</i> , 1997, 21, 519-523.	2.9	96
364	The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. <i>Trends in Neurosciences</i> , 1996, 19, 19-24.	4.2	420
365	The modulation of calcium currents by the activation of mGluRs. <i>Molecular Neurobiology</i> , 1996, 13, 81-95.	1.9	54
366	Role of Ca <sup>2+</sup> in striatal LTD and LTP. <i>Seminars in Neuroscience</i> , 1996, 8, 321-328.	2.3	28
367	A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. <i>Neurology</i> , 1996, 47, 557-562.	1.5	35
368	Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. I. Modulation of Corticostriatal Synaptic Transmission. <i>Epilepsia</i> , 1995, 36, 990-996.	2.6	51
369	Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. II. Modulation of High-Voltage-Activated Calcium Currents. <i>Epilepsia</i> , 1995, 36, 997-1002.	2.6	101
370	Outward potassium currents activated by depolarization in rat globus pallidus. <i>Synapse</i> , 1995, 20, 131-136.	0.6	12
371	Hypoxia-Induced Electrical Changes in Striatal Neurons. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1995, 15, 1141-1145.	2.4	17
372	Actions of Glycine on Non-dopaminergic Neurons of the Rat Substantia Nigra. <i>European Journal of Neuroscience</i> , 1995, 7, 2351-2354.	1.2	5
373	Vulnerability of Medium Spiny Striatal Neurons to Glutamate: Role of Na <sup>+</sup> /K <sup>+</sup> ATPase. <i>European Journal of Neuroscience</i> , 1995, 7, 1674-1683.	1.2	78
374	Transmitter Release Associated with Long-term Synaptic Depression in Rat Corticostriatal Slices. <i>European Journal of Neuroscience</i> , 1995, 7, 1889-1894.	1.2	37
375	On the mechanisms underlying hypoxia-induced membrane depolarization in striatal neurons. <i>Brain</i> , 1995, 118, 1027-1038.	3.7	89
376	Electrophysiology of dopamine D-1 receptors in the basal ganglia: Old facts and new perspectives. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1995, 19, 779-793.	2.5	5
377	Electrophysiological actions of felbamate on rat striatal neurones. <i>British Journal of Pharmacology</i> , 1995, 116, 2053-2061.	2.7	45
378	Long-Term Changes of Corticostriatal Synaptic Transmission: Possible Implication for Motor Memory. <i>Neuroscience</i> , 1995, 68, 89-103.		3

#	ARTICLE	IF	CITATIONS
379	Post-receptor mechanisms underlying striatal long-term depression. <i>Journal of Neuroscience</i> , 1994, 14, 4871-4881.	1.7	209
380	Activation of metabotropic glutamate receptors inhibits calcium currents and GABA-mediated synaptic potentials in striatal neurons. <i>Journal of Neuroscience</i> , 1994, 14, 6734-6743.	1.7	95
381	Basic Electrophysiology and Possible New Therapeutic Approaches to Movement Disorders. <i>Advances in Behavioral Biology</i> , 1994, , 229-237.	0.2	1
382	Heterogeneity of Metabotropic Glutamate Receptors in the Striatum: Electrophysiological Evidence. <i>European Journal of Neuroscience</i> , 1993, 5, 1370-1377.	1.2	66
383	Lithium Treatment Blocks Long-Term Synaptic Depression in the Striatum. <i>Neuron</i> , 1993, 10, 955-962.	3.8	43
384	Long-term synaptic depression in the striatum: physiological and pharmacological characterization. <i>Journal of Neuroscience</i> , 1992, 12, 4224-4233.	1.7	639
385	Long-term Potentiation in the Striatum is Unmasked by Removing the Voltage-dependent Magnesium Block of NMDA Receptor Channels. <i>European Journal of Neuroscience</i> , 1992, 4, 929-935.	1.2	380
386	Metabotropic Glutamate Receptors and Neuronal Toxicity. <i>Advances in Experimental Medicine and Biology</i> , 1992, 318, 137-145.	0.8	14
387	The guam toxin, B-N-methylamino-L-alanine (BMAA) activates metabotropic glutamate receptors in brain slices and neuronal cultures. <i>Pharmacological Research</i> , 1990, 22, 124.	3.1	0
388	Animal Models of Dystonia. , 0, , 49-52.		0